Board summary
Key figures
23,384
Registered population
62.7% aged 18–64
13.8%
Aged 65+
ICB 20.0% · England 17.9%
3.0%
Ethnic minority (non-White)
1.7% Asian · England 9.6%
4.9%
In IMD quintile 1
ICB 30.6% · England 21.0%
~959
Core20 residents (est.)
Resident basis; registered basis ~1,093 · see page 3
2,993
Hypertension register
+5.88% in 3 yrs · England +5.60%
217
SMI register
15.9% of Chorley's
303
COPD register
Reviews +10.72% in 3 yrs
Forecast to 2030
3,622
Hypertension patients, 2030
+629 on today
65.2%
QRISK ≥20% on statins, 2030
+4.34pp over 3 yrs
3.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
SMI physical health checks fell against England.
SMI BMI recording fell 6.8 pp over 2023 to 2025 to 73.4% (England +5.1 pp to 82.1%), which may reflect unverified recall gaps.
High-risk lipid and statin therapy lags comparators.
Lipid therapy for QRISK ≥ 20% is 55.4% (England 63.6%) and statins in non-CVD diabetes reach 62.2% (England 73.2%), suggesting unverified recall gaps.
Respiratory reviews and BP monitoring outperform England.
Annual COPD reviews reach 90.1% (England 76.4%, Chorley 82.4%) and recent hypertension BP readings reach 91.7% (England 90.0%), showing strong registered-patient review delivery.
Population, age and ethnicity
A younger population with 13.8% aged 65+ contrasts with 24 catchment care homes
Across 23,384 registered patients, 13.8% are aged 65+ (3,223 patients), well below Chorley (20.2%), the ICB (20.0%) and England (17.9%), while 23.5% are aged 0-17 (Chorley 19.3%, ICB 19.6%, England 19.6%). Buckshaw Village Health Centre is younger (28.1% aged 0-17; 8.3% aged 65+) than Adlington Medical Centre (18.3% aged 0-17; 20.0% aged 65+). Residential Census data indicates 97.0% White ethnicity (Chorley 95.6%, ICB 87.8%, England 81.1%) and 3.0% ethnic minority residents. Projected list growth to 2030 is 4.0% (Chorley 2.4%, ICB 1.7%, England 2.3%), though the projection method is unverified.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Chorley local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Chorley LA) | 1,635 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.4% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.4% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Chorley LA) | 743 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Chorley LA) | 10.4 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Overall Core20 share is 4.9%, with need concentrated at Adlington Medical Centre
Average IMD decile for CHORLEY AND SOUTH RIBBLE NETWORK PCN is 7.0, compared to England at 5.5 decile, Chorley at 6.5 decile, and NHS Lancashire and South Cumbria Integrated Care Board at 5.0 decile. The Core20 cohort is 4.9%, below Chorley (11.4 percent), NHS Lancashire and South Cumbria Integrated Care Board (30.6 percent), and England (21.0 percent). Modelled weighted practice Core20 share is 4.7%. Prioritising Adlington Medical Centre may offer greater operational impact, which is consistent with its higher captured Core20 share and estimated patient volume; local service uptake audits.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
217
SMI register
0.94% recorded prevalence
108
Learning disability register
0.47% recorded prevalence
24
Care homes, 769 beds
In the PCN catchment
9.3%
Provide unpaid care
Chorley, Census 2021
Learning disability prevalence is 0.5% (108 patients), trailing Chorley (0.6%), the ICB (0.6%) and England (0.6%). The mental illness register records 217 patients (0.9% vs Chorley 1.1%, ICB 1.2%, England 1.0%), alongside 24 catchment care homes (769 beds, occupancy unconfirmed). Crude prevalence does not establish under-detection or unmet need, requiring list validation.
Severe mental illness: physical health checks
Across 217 SMI patients, recorded BMI is 73.4% (England 82.1%) and BP checks reach 75.3% (England 83.4%). Over 2023 to 2025, BMI checks fell 6.8 pp (England +5.1 pp), which could reflect unverified physical health monitoring gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
2,993
Hypertension register
+5.88%
Register growth, 3 yrs
Chorley +6.44% · England +5.60%
+9.70pp
BP control, under 80
≤140/90 · +2.56pp aged 80+
+629
More patients by 2030
Forecast 3,622 (14.49%)
Hypertension case-finding and control
Recorded hypertension prevalence is 12.9% (2,993 patients), below Chorley (17.5%), the ICB (17.2%) and England (15.2%), ranging from 9.1% at Buckshaw Village Health Centre to 17.1% at Adlington Medical Centre. Lower recorded prevalence may reflect a younger population (13.8% aged 65+ versus 20.2% in Chorley), so the unadjusted register gap of +568 to +1,092 patients is an upper bound. Recent blood pressure readings reach 91.7% (England 90.0%), and treatment to target reached 68.7% (England 70.3%), rising +9.3 pp over 2023 to 2025 (England +2.5 pp). High blood pressure check coverage alongside below-average crude prevalence suggests case-finding audits in younger cohorts could test whether register gaps reflect age structure.
Lipids and statins
Lipid therapy trails England for QRISK ≥ 20% (55.4% vs 63.6%), diabetes without CVD (62.2% vs 73.2%), and CKD (63.2% vs 70.3%), with diabetes and CVD at 80.4% (England 84.4%). Lower coverage across cohorts could reflect unverified review or shared-care recording gaps, testable by targeted clinical audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 27,186 | £1.90 | £1.64 | £1.86 | £51,653 |
| Cardiovascular (all), 2025 | 46,625 | £3.75 | £3.38 | £3.33 | £174,844 |
In 2026, the PCN prescribed 27,186 lipid-regulating items at £1.90 per item (England £1.86, Chorley £1.79, ICB £1.64), spending £1,087 more than at England's unit cost and £7,068 more than at the ICB's unit cost. Prescribing review could test whether product selection explains unit-cost differences against local benchmarks.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+5.11%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+7.09%
Asthma prevalence, PCN 3-yr % change
COPD review coverage reaches 90.1% (England 76.4%, Chorley 82.4%), with registers expanding +14.3% over 2023 to 2025 across 303 patients. Asthma annual reviews achieve 74.3% (England 65.7%), though about 380 of 1,496 registered asthma patients lacked a recorded review. Second-hand smoking status was recorded for 96.3% of youth asthma patients (England 78.8%). Asthma prescribing for ages 5-19 is 930 per 1,000 (England 1,488), with Buckshaw Village Health Centre at 563 per 1,000 against 1,536 at Adlington Medical Centre, which could reflect unverified variations in paediatric management.
Cancer register and children's immunisation
Cancer register prevalence is 3.2% (748 patients), below England (3.8%) and Chorley (4.5%). In Q1 2025/26, 6-in-1 uptake reached 100.0% at 12 months, but age-5 boosters drop off: MMR2 is 88.4% (below the 95.0% target by 6.6 pp) and the 4-in-1 booster is 84.1% (below target by 10.9 pp). Across the PCN, MMR coverage drops 7.3 pp between dose one and dose two at age 5.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers in NHS Lancashire and South Cumbria ICB (4,642 of 8,863) were diagnosed at stage 1 or 2, trailing England (55.3%) and 22.6 pp below the 75.0% ambition by 2028. Staging completeness was 74.6% (8,863 of 11,883 cancers), and early-stage share fell 1.2 pp since 2013, leaving an annual scale gap of about 2,010 cases. These system figures do not measure PCN performance. Locally, cervical screening is 75.1% (England 66.8%) but fell 1.8% over 2023 to 2025 (England -1.0%), while breast screening is 67.6% (Chorley 72.7%, England 69.9%). Sustaining screening uptake is the PCN's chief lever to support system early detection.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, provider data shows Lancashire Teaching Hospitals NHS Foundation Trust met the 75.0% 28-day faster diagnosis standard at 82.9% (Wrightington, Wigan and Leigh 82.8%, East Lancashire 81.5%, England 79.3%, ICB 78.4%). However, its 62-day referral to treatment rate was 75.0%, below the 85.0% standard by 10.0 pp (Wrightington, Wigan and Leigh 76.8%, ICB 73.6%, East Lancashire 73.2%, England 71.2%). Diagnostic 6+ week waits reached 26.7% at Lancashire Teaching Hospitals (England 23.1%, Wrightington, Wigan and Leigh 14.4%, East Lancashire 3.2%), led by non-obstetric ultrasound at 28.2% and audiology at 83.0%.
| Pathways within standard (%) | Lancashire | Wrightington, Wigan and Leigh | East Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 82.90 | 82.80 | 81.50 | 78.39 | 79.32 |
| 31-day treatment (96%) | 89.43 | 89.04 | 98.11 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 75.04 | 76.78 | 73.16 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Lancashire | Wrightington, Wigan and Leigh | East Lancashire | England |
|---|---|---|---|---|
| MRI | 2.41 | 0.49 | 0.43 | 21.40 |
| CT | 14.97 | 7.78 | 0.15 | 9.92 |
| Echocardiography | 13.85 | 24.37 | 0.00 | 28.48 |
| Colonoscopy | 0.00 | 6.10 | 0.95 | 30.83 |
| Gastroscopy | 0.00 | 12.54 | 1.16 | 29.02 |
| All 15 DM01 tests | 26.65 | 14.36 | 3.25 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In provisional June 2026 experimental data, Lancashire upper-tier authority recorded 293,090 community care activities, 126,445 care contacts, 47,320 patients with a contact, and 20,415 referrals, with adults aged 65+ accounting for 56.9% of contacts. Across NHS Lancashire and South Cumbria Integrated Care Board, activity reached 533,345 care activities across 65,335 patients. These figures cover submitting providers only and do not represent unique PCN patients.
Practice variation and patient experience
Good practice experience spans 71.5% to 74.8% despite wider deprivation differences
In 2025/26, QOF overall achievement reached 98.3% at Adlington Medical Centre and 98.5% at Buckshaw Village Health Centre, exceeding the England average of 92.5%. Both practices attained 100.0% in vaccination and immunisation points (England 55.2%), while overall personalised care adjustment rates were 6.6% at Adlington Medical Centre and 5.9% at Buckshaw Village Health Centre (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Buckshaw Village | 80 | 2.7 | 54.7% | 76.4% | 74.8% |
| Adlington | 98 | 6.9 | 51.7% | 67.7% | 71.5% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Learning disability register fell 23.2% while diabetes control rose 12.0% over three years
Over 2023 to 2025, learning disability QOF prevalence fell 23.2% (England +5.4%, Chorley -8.3%). Severe mental illness physical health checks also eroded: BMI recording fell 6.8 pp to 73.4% (England +5.1 pp to 82.1%), and blood pressure checks fell 4.2 pp to 75.3% (England +4.4 pp to 83.4%). Conversely, non-frail diabetes HbA1c control rose 12.0% (England +4.4%) to 58.4% (England 57.4%), and heart failure reviews reach 84.2% (England 78.5%). These diverging trends could reflect unverified variations in recall systems, requiring clinical record audits to verify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Learning disability register
BMI record (SMI)
Heart failure reviews
Alcohol record (psychosis)
BP check (SMI)
BP control, under 80
Hypertension treated to target
Breast screening (53-70)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Chorley | Asset | PCN | Chorley |
|---|---|---|---|---|---|
| Care homes (catchment) | 24 (769 beds) | n/a | Schools (catchment) | 58 | n/a |
| Children's centres | 5 | 8 | Places of worship | 46 | 75 |
| Libraries | 2 | 4 | Primary schools (LA maintained) | 25 | 39 |
| Primary academies | 3 | 5 | Special schools | n/a | 2 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
SMI physical health check recall
Across 217 SMI patients (0.9% prevalence), BMI recording is 73.4% (England 82.1%, Chorley 80.6%), falling 6.8 pp over 2023 to 2025 (England +5.1 pp); BP checks are 75.3% (England 83.4%), falling 4.2 pp. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 2
Pharmacist-led lipid therapy review
Lipid therapy for QRISK ≥ 20% is 55.4% (England 63.6%, ICB 61.4%, Chorley 58.6%); statin treatment is 62.2% in non-CVD diabetes (England 73.2%) and 63.2% in CKD (England 70.3%). Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Learning disability register validation
Learning disability QOF prevalence is 0.5% (108 patients across 23,384 registered), below England, the ICB and Chorley (all 0.6%), after falling 23.2% over 2023 to 2025 (England +5.4%). For discussion: audit learning disability diagnostic codes against previous register cohorts and local authority social-care records where information-sharing agreements permit. Low cost, quick to run.
Evidence base: the register is the cohort for the annual health check and LeDeR learning; people with a learning disability die on average 20 years earlier and are a Core20PLUS5 PLUS group.
Policy anchor: annual health checks for 75% of people aged 14+ on the register (Network Contract DES); Oliver McGowan mandatory training.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Demographic resource alignment (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check audit (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Age-stratified hypertension audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Primary care access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · SMI physical health check recall (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 2 · Pharmacist-led lipid therapy review (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · CKD patients treated with lipid lowering therapy | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Learning disability register validation (p12) | Learning disability register · Learning disability: QOF prevalence · Registered population | 75% annual health checks (Network Contract DES) · Oliver McGowan | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
